Browse diseases

…y, receipt of 991-exposed CAR Ts significantly improved in vivo leukemia clearance and prolonged recipient survival, likely as a result …

…lls showed the best killing activity against most acute myeloid leukemia cells. Similar levels of cytotoxicity were exhibited by ESK3 Ab…

…s] were evaluated ( table 1). The most common malignancies were breast cancer (n=134/566, 24%), colorectal cancer (n=66/566, 12%), and leukem…

…ry sponsors. Oncology trials are most frequent, particularly in lung cancer, leukemia, and hepatocellular carcinoma, while combinatorial st…

…unotherapy for patients with refractory or relapsed lymphoma or leukemia. However, inefficient activity and insufficient persistence of …

…ble success in the treatment of some malignancies, particularly leukemia. However, there are multiple factors that limit the durability …

…tide (RMFPNAPYL), a clinically relevant target for leukemia and ovarian cancer. Millions of candidate minibinders are designed and scored for …

…herapy is largely limited to blood-based cancers, most commonly leukemia, and has little efficacy on solid tumors. Although this is the …

…esize they will have a similar response in solid tumors such as glioblastoma. NK cells are known to kill cells that downregulate MHC class 1…

…ollowing CAR-T therapy in patients with leukemia, lymphoma, and myeloma.Methods MEDLINE, Embase, Web of Science, and Cochrane CENTRAL d…